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in the FVT zone and may improve the clinical tolerance of these
tachycardias.
In re-entrant VT, the ability of ATP to terminate the arrhyth-
mia depends on the presence of an excitable gap (6) and on the
capability of the impulses to penetrate this gap. The main limiting
factor for penetrating the excitable gap is the distance to the
circuit; therefore, a long burst or a short-pacing CL is needed to
reach the FVT circuits. The first burst that we selected was shorter
and faster than those previously reported; nevertheless, the efficacy
and acceleration rate were similar, suggesting that the shorter CL
might compensate for a lower number of beats in the initial ATP
train (1). This observation may be important to decrease the delay
before the rescue HES is delivered if needed.
The number of FVTs is lower than in previous studies; however,
the proportion of patients with FVT is similar. The high propor-
tion of patients treated with beta-blockers and the inclusion of
nonischemic patients may explain this difference. The use of ATP
also appears to reduce the incidence of syncope/near-syncope
associated with an episode of FVT, presumably as a result of a
reduction in the VT duration. Interestingly, beta-blockers in-
creased the efficacy of ATP, indicating a possible influence of
autonomic tone in the maintenance of the VT (7,8).
This study suggests that a single, short ATP burst is efficient
and safe for the treatment of FVT, reducing the HES incidence
and arrhythmia-related symptoms. Nevertheless, the small number
of episodes and patients limits the power of these conclusions and,
therefore, a larger prospective study is required to validate these
data.
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Simvastatin Improves Endothelial Function in Patients With Rheumatoid Arthritis
To the Editor: Rheumatoid arthritis (RA) is the most common
systemic connective tissue disease and affects 2.1 million people in the
U.S., 1.5 million of whom are women (1). Patients with RA are at
increased risk of developing premature cardiovascular disease, which
shortens life expectancy by 3 to 18 years (1). These data provide the
rationale for preventive measures at an early stage before overt
cardiovascular disease becomes evident. Interestingly, endothelial
dysfunction, the key event in early atherogenesis, just recently has
been described in patients with RA both with high and low disease
activity (2).
Table 2. Analysis of Events per Patient
Variable Strategy A Strategy B Statistical Analysis
Number of patients with FVT (%) 10 (7.5) 13 (9.8) OR 1.33 (95% CI 0.56–3.15); p  0.51
Mean of FVT per patient 0.20  1.01 0.14  0.50 95% CI of the difference: 0.14, 0.25; p  0.6
Number of patients with HES secondary to
FVT (%)
2 (1.5) 12 (9) OR 0.27 (95% CI 0.07–0.99); p  0.01†
Mean of HES per patient secondary to FVT 0.02  0.12 0.14  0.54 95% CI of the difference: 0.21, 0.02; p  0.015
HES/FVT (%) 3/27 (11) 20/22 (91) OR 0.14 (95% CI 0.04–0.40); p  0.001
FVT episode duration, s (range) 9.3  8.4 (5–40) 14.8  4.6 (8–29) 95% CI of the difference: 9.96 to 1.07; p  0.016
Syncope for FVT (%) 2/27 (7.4)* 5/22 (22.7) OR 0.21 (95% CI 0.04–1.56); p  0.21†
Near-syncope for FVT (%) 1/27 (3.7) 12/22 (54) OR 0.10 (95% CI 0.01–0.07); p  0.001†
Syncope/near-syncope for FVT (%) 3/27 (11) 17/22 (77) OR 0.18 (95% CI 0.06–0.52); p  0.001
Mean CL 288  15 284  16 0.48
*The two episodes of syncope in strategy A occurred secondary to fast VT unsuccessfully treated by ATP. †Fisher exact test.
CI  confidence interval; CL  cycle length; FVT  fast ventricular tachycardia; HES  high-energy shocks; OR  odds ratio.
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Statins have demonstrated beneficial effects in primary and
secondary prevention trials in a wide range of cardiovascular risk
categories (3). In addition to their potent lipid-lowering effects,
statins recently have been ascribed anti-inflammatory, antithrom-
botic, antioxidative, and immunomodulatory properties (4,5).
Hence, the aim of the present study was to evaluate the effects of
statin therapy on vascular function, plasma lipids, and oxidative
stress in patients with RA who have normal cholesterol levels.
The present study was a randomized, crossover, double-blind
and placebo-controlled interventional trial. Twenty patients were
assigned randomly to receive either simvastatin 40 mg/day for four
weeks followed by four weeks of matching placebo or vice versa.
Endothelial function and laboratory and clinical parameters were
assessed at baseline and the end of each treatment phase as
described previously (2). Inclusion criteria were diagnosis of RA
according to the revised American College of Rheumatology
diagnostic criteria (6), age 18 to 65 years, and active disease,
defined as Disease Activity Score in 28 joints of 2.6 (Table 1).
Exclusion criteria were previous myocardial infarction, coronary
intervention or coronary surgery, previous treatment with statins in
the last six months, uncontrolled hypertension (160/90 mmHg),
dyslipidemia (low-density lipoprotein [LDL] cholesterol 4.9
mmol), smoking, and kidney (creatinine 150 mol/l) or liver
disease. Disease-modifying antirheumatic drug therapy was un-
changed for three months before inclusion to the study and
remained stable throughout. Of the 20 patients studied, 13
received methotrexate, with an average dose of 16 mg/week, that
was administered subcutaneously once a week. Concomitant med-
ication, including corticosteroids (average oral dose of 3.4 mg/day)
or nonsteroidal anti-inflammatory drugs and folic acid (average
dose 7 mg/week), remained unchanged throughout the study
course. Each patient gave written informed consent before entry
into the study. The study protocol was approved by the local ethics
committee of the University Hospital of Zürich.
This study is the first to show that statin therapy reduces plasma
cholesterol and oxidative stress in the context of ongoing inflam-
mation, thus resulting in an improvement of vascular function in
normocholesterolemic patients with RA. Flow-mediated dilatation
as a measurement of endothelial function improved after four
weeks of treatment with simvastatin compared with placebo (5.5
0.7% vs. 3.8  0.4%; p  0.02) (Fig. 1A). Stratified by median
split, patients with higher markers of inflammation (n  10;
C-reactive protein 10 mg/l) showed a significantly higher im-
provement in flow-mediated dilation than patients with low
markers of inflammation (n  10; C-reactive protein 10 mg/l; p
 0.04) (Fig. 1B). There was no difference concerning the
treatment sequence. Total cholesterol, LDL cholesterol, and
apolipoprotein B (apoB) were lowered by simvastatin therapy by
21%, 34%, and 33%, respectively (p 0.0001) (Table 2). Oxidized
low-density lipoproteins (oxLDLs), as well as the ratio oxLDL to
LDL (p  0.001 and p  0.03, respectively), were reduced by
simvastatin treatment (Table 2), indicating attenuated oxidative
stress.
Although modest but clinically apparent anti-inflammatory
effects of atorvastatin were reported just recently by McCarey et al.
(7), the effects of statins on vascular function in systemic connec-
tive tissue disease, particularly in patients with RA who had low
serum cholesterol levels without overt cardiovascular disease, were
unclear before this study. The improvement of endothelial func-
tion in the present study may be explained partly by the reduction
of LDL cholesterol and apoB. The sum of apoB concentrations in
all atherogenic particles provides better risk prediction than LDL
Table 1. Baseline Characteristics
Baseline
(n  20)
Age (yrs) 57  2
Women 14 (70)
Positive rheumatoid factor 15 (75)
Erosive disease 14 (70)
Disease duration (yrs) 14  2
Cardiovascular risk factors
Smoking in the past (%) 5 (25)
Arterial hypertension (%) 8 (40)
Diabetes mellitus (%) 0
Positive family history (%) 2 (10)
Body mass index (kg/m2) 23.8  0.6
Cardiac medication (%)
Low-dose aspirin 3 (15)
Beta-blockers 3 (15)
Angiotensin converting enzyme inhibitors/
angiotensin II receptor blockers
4 (20)
Antirheumatic therapy
Disease-modifying antirheumatic drugs 17 (85)
Methotrexate 13 (65)
Other disease-modifying antirheumatic drugs 4 (20)
Prednisone 11 (55)
Nonsteroidal anti-inflammatory drugs 17 (85)
Results expressed as mean  SEM, or n (%).
Figure 1. (A) Flow-mediated dilation was increased after four weeks of
simvastatin therapy (p  0.02 vs. placebo). Endothelium-independent
function assessed by glycerol trinitrate (GTN)-induced vasodilation re-
mained unchanged (p  0.58 vs. placebo). (B) Flow-mediated dilation in
10 patients with high and in 10 patients with low inflammation markers.
Patients with elevated markers of systemic inflammation (n  10;
C-reactive protein [CRP] 10 mg/l) showed pronounced improvement in
flow-mediated dilation (vs. patients with CRP 10 mg/l, n  10; p 
0.04). Open bars  placebo; closed bars  simvastatin.
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cholesterol alone, particularly in individuals with normal and low
LDL cholesterol concentrations (8).
Inflammation is a hallmark both of atherosclerosis and RA
(4,9), and striking similarities exist between the pathogenesis of
atherosclerotic vascular disease and RA (9). Thus, mechanisms
that are responsible for synovial inflammation and subsequent joint
destruction may not only be confined to the joints but also evident
in the vessel wall, explaining the excess of cardiovascular disease in
RA. Interestingly, the improvement of endothelial function in the
present study was more pronounced in patients with elevated
markers of inflammation, thus extending findings of a recent study
demonstrating modest but clinically apparent anti-inflammatory
effects of atorvastatin in patients with RA (7).
Endothelial dysfunction is characterized by impaired bioavail-
ability of nitric oxide due to decreased production or accelerated
degradation of nitric oxide by reactive oxygen species (10). Indeed,
in the present study, simvastatin reduced formation of reactive
oxygen species, as indicated by a reduction of oxLDL. Importantly,
the reduction of the oxLDL/LDL ratio exceeded that of LDL
alone, clearly indicating attenuation of oxidative stress. Oxidized
LDL is not only an index of lipid peroxidation, but it also causes
endothelial dysfunction itself through the impairment of signal
transduction from endothelial cell surface receptors, inhibition of
nitric oxide synthase activity, and inactivation of nitric oxide
released from endothelial cells (10).
In conclusion, the reduction of proatherogenic lipids and
markers of oxidative stress result in an improvement of vascular
function, indicating that statins may hold the potential as a novel
add-on therapy in the treatment of RA. Yet, the potential hepato-
toxicity of statins, especially in combination with other disease-
modifying antirheumatic drug therapies, is of clinical concern and
needs to be addressed in future clinical studies. The definitive answer
as to the net effect of statins on cardiovascular events in patients with
RA, can only be provided by well-designed, large-scale clinical trials.
Acknowledgments
The authors thank the contributing staff of the Departments
of Cardiology and Rheumatology of the University Hospital
of Zurich as well as the Swiss Polyarthritis Association.
Frank Hermann, MD
Adrian Forster, MD
Rémy Chenevard, MD
Frank Enseleit, MD
David Hürlimann, MD
Roberto Corti, MD
Lukas E. Spieker, MD
Diana Frey, MD
Matthias Hermann, MD
Walter Riesen, PhD, MD hc
Michel Neidhart, PhD
Table 2. Clinical Parameters, Laboratory Values, and Vascular Function at the End of the Study
Simvastatin
(n  20)
Placebo
(n  20) p Value
Vital signs
Blood pressure, mm Hg 126/77  4/2 131/82  5/2 0.83/0.07
Mean blood pressure, mm Hg 93.3  2.7 98.1  3.1 0.21
Heart rate, beats/min 66  2 69  2 0.37
Laboratory
Total cholesterol, mmol/l 4.1  0.3 5.2  0.3 0.0001
LDL cholesterol, mmol/l 2.0  0.2 3.0  0.2 0.0001
Oxidized LDL, U/l 42.6  4.5 63.0  4.9 0.0001
Oxidized LDL/LDL ratio 23.3  2.2 32.3  2.8 0.03
HDL cholesterol, mmol/l 1.5  0.1 1.5  0.1 0.39
Triglycerides, mmol/l 1.3  0.2 1.6  0.2 0.06
Apolipoprotein B, g/l 0.7  0.1 1.1  0.1 0.0001
Lipoprotein(a), mg/l 162  55 165  55 0.60
C-reactive protein, mg/l 20.9  7.5 22.9  8.8 0.58
Erythrocyte sedimentation rate, mm/h 23.1  5.1 23.0  4.9 0.96
Interleukin-1, pg/ml 0.1  0.1 0.2  0.1 0.77
Interleukin-6, pg/ml 9.2  2.2 8.5  2.0 0.83
Tumor necrosis factor-alpha, pg/ml 10.3  7.7 9.2  7.0 0.16
Glucose, mmol/l 5.1  0.3 5.0  0.2 0.69
Creatinine, mol/l 78.2  2.9 77.3  2.7 0.42
Creatine kinase, U/l 76.5  8.0 74.7  9.4 0.99
ASAT, U/I 24.2  2.3 20.8  1.3 0.03
ALAT, U/l 26.6  4.2 20.3  1.6 0.11
Vascular function measurements
Arterial diameter, mm 4.3  0.16 4.4  0.16 0.62
Flow-mediated vasodilation, % 5.5  0.7 3.8  0.4 0.02
Nitrogylcerin-induced vasodilation, % 12.8  1.2 11.7  1.5 0.58
Brachial artery intima media thickness 0.4  0.10 0.4  0.05 0.17
Disease activity score (DAS28) 3.9  0.3 3.7  0.3 0.38
RADAI 2.2  0.4 2.4  0.5 0.21
Results expressed as mean  SEM.
ALAT  alanine aminotransferase; ASAT  aspartate aminotransferase; HDL  high-density lipoprotein; LDL 
low-density lipoprotein; RADAI  Rheumatoid Arthritis Disease Activity Index.
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Impact of Microvascular Complications on Outcome After Coronary Stent Implantations
in Patients With Diabetes
To the Editor: Bare metal stent implantation is less effective in
patients with diabetes than in patients without diabetes (1–3).
Microvascular complications have been identified as risk markers
for cardiovascular events in patients with diabetes (4–7). We
evaluated the impact of microvascular complications (nephropathy
and retinopathy) on the outcome after elective coronary bare metal
stent implantation in patients with type 2 diabetes.
A total of 283 consecutive patients with type 2 diabetes mellitus
who successfully underwent their first elective bare metal stent
implantation at our institution from January 2000 to June 2003
were included into the analysis. Diabetic retinopathy was detected
within one week before or after the procedure. Microalbuminuria
(protein excretion of 30 to 300 mg/24 h) was determined the day
before the procedure.
The principal characteristics of the 283 patients are summarized
in Table 1. At 12 months, major adverse cardiac events (major
adverse clinical event [MACE], i.e., death of any cause, nonfatal
myocardial infarction, repeat percutaneous procedure, and bypass
surgery) occurred in 34 of the 161 patients (21%) in the group
without microvascular complications, in 18 of the 45 patients
(40%) in the nephropathy group, in 22 of the 43 patients (51%) in
the retinopathy group, and in 25 of the 34 patients (73.5%) in the
group with both microvascular complications (p  0.001) (Fig. 1).
The influence of clinical, angiographic, and procedural variables on
Figure 1. Kaplan-Meier event-free survival at 12 months in four groups defined according to the presence of microvascular complications.
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